ImPact Biotech Announces Treatment of First Patient in Phase 1 Clinical Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC)
Previously inoperable patient converted to eligible for resection, underwent pancreaticoduodenectomy, following single course of treatment with Padeliporfin VTP – TEL AVIV, Israel, June 05, 2025 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stagebiotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced that the first … Continued
Read More
ImPact Biotech Presents Interim Analysis from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at ASCO 2025
Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) – Padeliporfin VTP treatment continues to be safe and well-tolerated, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase (MTP) – Interim analysis follows evaluation of 50% … Continued
Read More
ImPact Biotech Announces Late-Breaking Podium Presentation at ASCO 2025 Highlighting ENLIGHTED Study Interim Analysis
Company to present interim update from ENLIGHTED Phase 3 Study in LG UTUC following assessment of 50% of targeted total evaluable patient enrollment– TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnologycompany focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy totreat a range of solid tumors, today announced … Continued
Read More
ImPact Biotech Presents Updated Efficacy Data from Evaluation of Padeliporfin VTP in LG UTUC and IntermediateRisk Prostate Cancer at AUA 2025
Complete response (CR) observed in 79% (26/33) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) of the ENLIGHTED Phase 3 trial evaluating Padeliporfin VTP in UTUC – Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in … Continued
Read More
ImPact Biotech Announces New Data Presentations at AUA 2025 Highlighting Safety and Efficacy of Padeliporfin VTP
Company to present updated preliminary results from ENLIGHTED Phase 3 Study in LG UTUC Additional podium presentation to provide updates from long-term evaluation of Padelipor n VTP in intermediate-risk prostate cancer TEL AVIV, Israel, April 11, 2025 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padelipor n vascular targeted photodynamic (VTP) … Continued
Read More
ImPact Biotech Presents Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at SUO 2024
Complete response (CR) observed in 85% (17/20) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase TEL AVIV, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) — ImPact … Continued
Read More
ImPact Biotech Presents Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin n VTP in Low Grade UTUC at EMUC 2024
Complete response (CR) observed in 86% (12/14) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) — ImPact … Continued
Read More
ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024
TEL AVIV, Israel, Oct. 25, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporn vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced an abstract including interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporn VTP treatment of patients with low-grade upper … Continued
Read More
ImPact Biotech to Present at Oppenheimer Private Life Sciences Company Showcase
TEL AVIV, Israel, Sept. 25, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced that management will present a corporate overview at the Oppenheimer Private Life Sciences Company Showcase on October 1 st, 2024 in New … Continued
Read More
ImPact Biotech Receives a €13.5M Investment Commitment from the European Innovation Council’s Accelerator Program
TEL AVIV, Israel, July 24, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padelipor n vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced investment commitment of €13.5M from the European Innovation Council’s (EIC) Accelerator program, including a grant of €2.5M and a conditional equity investment … Continued
Read More